Search

Displaying results 1911 - 1920 of 6076 in total
  1. Drug

    Bimatoprost

    go.drugbank.com/drugs/DB00905
    ApprovedInvestigational

    [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug

  2. Drug

    Calcium glucoheptonate

    go.drugbank.com/drugs/DB00326
    ApprovedInvestigational

    Calcium is also needed for the heart, muscles, and nervous system to work properly. … Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium.

  3. Drug

    Donislecel

    go.drugbank.com/drugs/DB17961
    Approved

    [L47196] Overall, 21 patients achieved insulin independence for a year or more, with 11 patients not needing insulin for 1 to 5 years and 10 patients for more than 5 years. … Donislecel is the first allogeneic pancreatic islet cellular from deceased donor pancreatic cells used for the treatment of adult type 1 diabetes with unsuccessful control of glycated hemoglobin, despite

  4. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [A252667] Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like … Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic.

  5. Drug

    CMC 001

    go.drugbank.com/drugs/DB05353
    Investigational

    CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.

  6. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    It was FDA approved in 2015 for the treatment of basal cell carcinoma.

  7. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471] … Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM).

  8. Drug

    DL-dimyristoylphosphatidylglycerol

    go.drugbank.com/drugs/DB11284
    Approved

    DL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.

  9. Drug

    Levamisole

    go.drugbank.com/drugs/DB00848
    ApprovedInvestigationalVet approvedWithdrawn

    [A178117] This drug has also been used in combination with other drugs for the treatment of various cancers. … Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections.

  10. Drug

    Dichlorobenzyl alcohol

    go.drugbank.com/drugs/DB13269
    Approved

    Dichlorobenzyl alcohol is a mild antiseptic with a broad spectrum for bacterial and virus associated with mouth and throat infections. … [L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773]